Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 1999

View Archived Issues

Antifungal agent DuP-991 available for licensing from BTG

Bioniche's IND for bladder cancer treatment granted IND approval

FDA approves phase III protocol for Cypros' Cordox

FDA expands HUD designation for Ortec's Composite Cultured Skin

King completes acquisition from Lilly of U.S. rights to Lorabid

AdProTech and Avecia begin scale-up of APT-070

Medco issued patent covering allosteric adenosine modulators

Texas Biotechnology corrects NDA amendment for Novastan

Japan is country of first launch for migraine prevention agent

Tanabe Seiyaku-Pharmacia & Upjohn collaboration provides new leads in inflammation research

ACS presentation for Parke-Davis's selective NR1a/2B receptor antagonist PD-188669

News from ACS: Abbott and Icos describe antiinflammatory ICAM-1 inhibitor

MRS-1595: a novel adenosine antagonist selective for the A2B receptor

Yoshitomi discloses cytokine production inhibitors for treating and preventing allergic reactions

Retrospective study supports safety of xenotransplantation

More antiviral agents against CMV discovered at Bayer

Anticoagulant factor Xa inhibitors reported by Mochida

Antimycotic agents, triazole derivatives prepared and evaluated by Japanese lab

Tanabe Seiyaku pursues integrin receptor antagonists, with interesting results

InterMune files BLA for Actimmune for treatment of osteopetrosis

Berlex acquires marketing rights to Campath

BioCryst reports initial phase II results from worldwide influenza collaboration

Cardioselective potassium channel blocker advances to phase II trials at HMR

Academic researchers identify MAb as effective treatment for PCP addiction

Allergan receives approvable letter for Restasis

FDA grants priority review to Visudyne NDA

ACS presentation for new factor Xa inhibitor from Rhone-Poulenc Rorer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...